IRIS
ARMUZZI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.459
AS - Asia 9.171
EU - Europa 3.199
SA - Sud America 1.761
AF - Africa 250
Continente sconosciuto - Info sul continente non disponibili 174
OC - Oceania 7
Totale 29.021
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.168
SG - Singapore 5.979
BR - Brasile 1.471
CN - Cina 1.320
VN - Vietnam 826
FI - Finlandia 567
IT - Italia 539
DE - Germania 466
IE - Irlanda 437
FR - Francia 297
IN - India 257
GB - Regno Unito 224
HK - Hong Kong 220
NL - Olanda 157
RU - Federazione Russa 130
CA - Canada 129
AR - Argentina 108
BD - Bangladesh 91
NG - Nigeria 88
MX - Messico 87
IQ - Iraq 65
SE - Svezia 62
PL - Polonia 58
ZA - Sudafrica 53
TR - Turchia 52
EC - Ecuador 49
BE - Belgio 42
JP - Giappone 40
ID - Indonesia 39
PK - Pakistan 37
CO - Colombia 36
ES - Italia 35
UA - Ucraina 33
VE - Venezuela 32
SA - Arabia Saudita 30
CZ - Repubblica Ceca 28
IR - Iran 24
UZ - Uzbekistan 23
CL - Cile 22
MA - Marocco 22
IL - Israele 21
TN - Tunisia 20
PY - Paraguay 18
EG - Egitto 17
JO - Giordania 17
KE - Kenya 16
LT - Lituania 16
MY - Malesia 16
AE - Emirati Arabi Uniti 14
AT - Austria 14
HN - Honduras 13
JM - Giamaica 13
NP - Nepal 13
CR - Costa Rica 12
PE - Perù 12
PT - Portogallo 11
DO - Repubblica Dominicana 10
PH - Filippine 10
RO - Romania 10
TT - Trinidad e Tobago 10
DZ - Algeria 8
GT - Guatemala 8
KZ - Kazakistan 8
OM - Oman 8
UY - Uruguay 8
AZ - Azerbaigian 7
CH - Svizzera 7
LV - Lettonia 7
PS - Palestinian Territory 7
AL - Albania 6
AU - Australia 6
BG - Bulgaria 6
BY - Bielorussia 6
ET - Etiopia 6
GR - Grecia 6
KG - Kirghizistan 6
BO - Bolivia 5
EE - Estonia 5
LB - Libano 5
RS - Serbia 5
BA - Bosnia-Erzegovina 4
CI - Costa d'Avorio 4
KW - Kuwait 4
MN - Mongolia 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
TW - Taiwan 4
HR - Croazia 3
KH - Cambogia 3
MK - Macedonia 3
SC - Seychelles 3
SI - Slovenia 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BH - Bahrain 2
BN - Brunei Darussalam 2
CY - Cipro 2
DK - Danimarca 2
GH - Ghana 2
Totale 28.817
Salva come PNG Salva come JPEG
Città #
Singapore 2.468
Chandler 1.936
Ashburn 1.630
San Jose 1.386
The Dalles 1.026
Dallas 915
Shanghai 656
Council Bluffs 610
Helsinki 564
Dublin 437
Boardman 420
Princeton 409
Lawrence 408
New York 340
Wilmington 291
Ho Chi Minh City 281
Los Angeles 250
Beijing 242
Paris 227
Hanoi 205
Hong Kong 201
Milan 188
Santa Clara 188
Falkenstein 187
Amsterdam 145
Phoenix 141
São Paulo 133
Pune 115
London 104
San Mateo 100
Ann Arbor 88
Rome 85
Benin City 84
Buffalo 64
Seattle 64
Rio de Janeiro 58
Warsaw 53
Leawood 50
Orem 47
Moscow 43
Brooklyn 41
Munich 41
Frankfurt am Main 40
Belo Horizonte 39
Brussels 39
Chennai 39
Chicago 37
Toronto 36
Da Nang 35
Montreal 34
Fairfield 32
Mexico City 32
Porto Alegre 32
San Francisco 31
Assago 30
Atlanta 30
Curitiba 30
Haiphong 30
Woodbridge 29
Brasília 28
Tokyo 27
Johannesburg 25
Charlotte 24
Brno 22
Tashkent 22
Figino 21
Houston 21
Guayaquil 20
Baghdad 19
Boston 19
Goiânia 19
Columbus 18
Dhaka 18
Mumbai 17
Stockholm 17
Amman 16
Campinas 16
Guarulhos 16
Nairobi 16
Naples 16
Ankara 15
Hillsboro 15
Manchester 15
Poplar 15
Riyadh 15
Biên Hòa 14
Turin 14
Bắc Ninh 13
Denver 13
Bologna 12
Oshnaviyeh 12
Quito 12
Bogotá 11
Erbil 11
Fortaleza 11
Las Vegas 11
Osasco 11
Reston 11
Tunis 11
Kocaeli 10
Totale 18.165
Salva come PNG Salva come JPEG
Nome #
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 630
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 194
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate 128
Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation 124
Adalimumab in active ulcerative colitis: A "real-life" observational study 114
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 112
Biological therapies for inflammatory bowel disease: Research drives clinics 111
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 107
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 106
13C-Breath Tests in the study of microsomal liver function 104
13C-breath tests in the study of mitochondrial liver function 102
Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease 102
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 101
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 101
Adalimumab in the treatment of immune-mediated diseases 98
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 98
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates 94
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 94
DNA mismatch repair gene mutations in hereditary non polyposis colorectal cancer (HNPCC) and putative HNPCC (P-HNPCC) Italian families 94
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 92
3-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure H-pylori infection 91
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy 91
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 90
Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease 90
Efficacy and tolerability of antibiotics in patients undergoing H-pylori eradication 90
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 89
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 88
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study 86
Prevalence of and risk factors for Helicobacter pylori infection among healthcare workers at a teaching hospital in Rome: the Catholic University Epidemiological Study 86
Acute pancreatitis and parathyroid carcinoma: a case report and literature review 84
Association of Depression With Incident Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis 84
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 83
H-pylori poliantibiotic resistant strains in dyspeptic patients not eradicated by two consecutive triple eradication regimens 83
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study 83
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 82
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 82
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study 82
Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn's Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal Transition 81
Activity of Crohn's disease and small bowel contract-enhanced ultrasound findings 81
Ustekinumab in the management of Crohn's disease: Expert opinion 81
Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease 80
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 80
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 80
Antibodies to Saccharomyces cerevisiae: Are they useful in clinical practice? 79
ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment 79
Pomegranate Extract Affects Gut Biofilm Forming Bacteria and Promotes Intestinal Mucosal Healing Regulating the Crosstalk between Epithelial Cells and Intestinal Fibroblasts 78
H-pylori gastric infection and rheumatic diseases 77
Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation 77
Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach 77
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 77
Antibiotic resistance of H-pylori strains obtained by dyspeptic patients not eradicated by two consecutive eradication regimens 76
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 76
FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF alpha Agents 76
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study 76
Usefulness of C-13-methionine breath test as a non-invasive and dynamic tool to evaluate residual hepatic mitochondrial function 75
A novel pathogenic role for microvasculature in inflammatory bowel disease 75
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study 74
HELICOBACTER-PYLORI GASTRITIS WITH CYTOTOXIN ASSOCIATED PROTEIN ANTIBODIES (CAGA) - A COMPUTER-AIDED EVALUATION OF INFLAMMATORY CELL INFILTRATION IN THE LAMINA PROPRIA, ATROPHIC GASTRITIS AND ACQUIRED MALT 74
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment 74
Haplotypic analysis of heat shock protein 70 (HSP70) single nucleotide polymorphisms (SNPs) in susceptibility and phenotype of inflammatory bowel disease (IBD) 73
The learning curve for using intestinal ultrasonography 73
Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study 73
Family history of peptic ulcer and a positive C-13 urea breath test are predictive of gastroduodenal ulcer disease in uninvestigated dyspeptic patients 73
Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus 73
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 73
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease 72
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 72
Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis 71
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study 70
Dietary Fiber in Inflammatory Bowel Disease: Are We Ready to Change the Paradigm? 70
Aminopyrine and methacetin 13C-breath tests to assess hepatic function in HCV-related chronic liver disease 70
Long-term scheduled therapy with infliximab in inflammatory bowel disease 70
Role of sucralfate in gastrointestinal diseases 70
Role of helicobacter pylori in gastroesophageal reflux disease 70
Artificial intelligence and inflammatory bowel disease: Where are we going? 70
Helicobacter pylori eradication ameliorates migraine: An extended follow up study 69
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 69
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by C-13-octanoate breath test 69
C-13 urea breath test for predicting resistance to therapy in Helicobacter pylori infection 69
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study 69
Disease patterns in late-onset ulcerative colitis: Results from the " IG-IBD ""AGED study""" 69
Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality 69
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease 69
Incidence and symptoms related to Helicobacter pylori infection in dyspeptic patients 68
INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS ON ANTI TNF-ALPHA THERAPY: RESPONSE TO THE INFLUENZA A/H1N1 VACCINE 68
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders 68
Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study 68
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study 68
IBD: Infliximab dose optimization in IBD-proactive or reactive? 68
Non-invasive assessment of human hepatic mitochondrial function through the C-13-methionine breath test 68
The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars 68
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use 68
New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report 67
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 67
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease 67
Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians 66
Occurence of systemic endothelial dysfunction in patients affected by ulcerative colitis and Crohn disease 66
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results 66
Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study 66
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 66
Totale 8.711
Salva come PNG Salva come JPEG
Categoria #
all - tutte 190.201
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 190.201
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022315 0 3 15 68 5 3 9 37 27 33 67 48
2022/20235.528 881 67 455 612 462 568 7 567 1.025 476 349 59
2023/20243.458 228 332 814 263 115 396 188 115 29 219 345 414
2024/20254.764 100 30 50 64 60 469 230 321 931 1.287 619 603
2025/202613.039 1.878 845 907 1.095 470 710 3.883 649 691 815 409 687
2026/20271.377 515 862 0 0 0 0 0 0 0 0 0 0
Totale 29.021